While the fundamental principles of the regulatory process are similar worldwide, specific requirements and timelines can vary. For instance, the FDA may have different criteria compared to the EMA. Additionally, some countries may have expedited pathways for approving treatments for serious or life-threatening conditions, such as the FDA's Breakthrough Therapy designation or the EMA's PRIME scheme.
